Global Gastric Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Global Gastric Cancer Diagnostics Market - Industry Trends and Forecast to 2030

The global gastric cancer diagnostics market is projected to register a CAGR of 8.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Gastric Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Gastric (Pre) Cancer Screening Tests/Physical Exam, Confirmatory Tests), Age Group (Adult, Pediatric, and Geriatrics), Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East And Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast To 2030

Some of the major factors contributing to the growth of the gastric cancer diagnostics market are:
• Rising healthcare expenditure for better health services
• Rising Awareness about gastric cancer
• Increase in diagnostic procedures for gastric cancer

Market Players:

Some of the key market players in the global gastric cancer diagnostics market are listed below:
• BIOMÉRIEUX
• Myriad Genetics, Inc.
• ACON Laboratories, Inc.
• Teco Diagnostics
• Vela Diagnostics
• Abbott
• AdvaCare Pharma
• MiRXES
• Fujirebio (An H.U. Group company)
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• GENERAL ELECTRIC COMPANY
• Agilent Technologies, Inc.
• Endofotonics Pte Ltd
• Biohit Oyj
• BIOCEPT, INC.
• FOUNDATION MEDICINE, INC.
• DiaSorin S.p.A
• Paragon Genomics, Inc.
• QIAGEN

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.